Bedford, Massachusetts, USA, November 17, 2026
Werfen has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ROTEM® sigma complete cartridge for use in trauma patients, expanding the clinical applications of its automated blood coagulation testing technology in the United States. The newly cleared indication allows healthcare professionals to use the ROTEM sigma viscoelastic testing system to assess peri-operative hemorrhage and thrombosis in trauma, supporting the evaluation and management of coagulation abnormalities during critical bleeding events. The regulatory milestone extends the system’s applications beyond its existing use in cardiovascular surgery and liver transplantation, introducing an additional diagnostic option for hospitals, emergency departments and acute care facilities. Traumatic injuries account for approximately 10% of deaths worldwide, while uncontrolled bleeding remains one of the leading causes of potentially preventable death following severe trauma. By providing rapid information about blood clot formation and stability, Werfen aims to support more informed clinical decisions during time-sensitive trauma resuscitation. The clearance strengthens the company’s acute care diagnostics portfolio and highlights the growing importance of point-of-care coagulation testing in modern emergency and surgical care.
FDA Clearance Expands ROTEM sigma into Trauma Care
The FDA clearance represents an important expansion of the ROTEM sigma thromboelastometry system, enabling its use with the ROTEM sigma complete cartridge for coagulation assessment in trauma patients. Previously, the system’s approved applications included assessing peri-operative hemorrhage and thrombosis in cardiovascular surgery and liver transplantation using the ROTEM sigma complete + hep cartridge. The new indication extends its diagnostic capabilities into trauma-related bleeding management. Trauma-induced coagulopathy, a condition involving abnormalities in the blood clotting process following severe injury, can complicate treatment and increase the risk of serious bleeding. Rapid assessment of coagulation status is therefore essential for healthcare professionals managing critically injured patients. The ROTEM sigma system is designed to evaluate the viscoelastic properties of citrated whole blood, providing information about the different stages of clot formation and breakdown. Importantly, the FDA-cleared system is indicated for adult patients aged 21 years and older in point-of-care and laboratory settings. It is not intended for use in pre-hospital trauma settings. The company highlighted that the expanded indication supports the growing clinical role of viscoelastic testing as part of goal-directed bleeding management and coagulation support.
Automated Cartridge Technology Enables Real-Time Coagulation Analysis
The ROTEM sigma system uses fully automated viscoelastic testing technology to assess three important characteristics of blood coagulation: clot initiation, clot firmness and clot stability. Its ROTEM sigma complete cartridge contains four single-use assays, namely INTEM C, EXTEM C, FIBTEM C and APTEM C, which evaluate different aspects of the coagulation process. INTEM C assesses coagulation through the intrinsic pathway, while EXTEM C evaluates the extrinsic pathway. FIBTEM C assesses clot firmness after blocking the contribution of platelets, and APTEM C evaluates coagulation after inhibiting fibrinolysis. Together, these tests provide healthcare professionals with a broader understanding of coagulation abnormalities and help inform individualized treatment strategies. The platform also incorporates closed-tube direct sampling, automated assay initiation, integrated quality control and continuous internal system monitoring, reducing manual handling and operator-dependent variability. Its intuitive touchscreen interface and room-temperature cartridge storage are designed to simplify laboratory and point-of-care workflows. In addition, large, easy-to-interpret TEMograms and GEMweb® Live connectivity provide clinicians with real-time visibility into coagulation dynamics. ROTEM sigma results must be interpreted alongside the patient’s clinical condition and other laboratory findings rather than being used as the sole basis for diagnosis or treatment decisions.
Werfen Strengthens Acute Care Diagnostic Portfolio
The latest FDA clearance reinforces Werfen’s commitment to advancing acute care diagnostics and improving bleeding management through specialized medical technologies. Founded in 1966, the company develops and manufactures diagnostic instruments, reagents, automation systems and data management solutions for hospitals and clinical laboratories worldwide. Its acute care diagnostics portfolio includes ROTEM viscoelastic testing systems, GEM Premier blood gas analysers, Hemochron coagulation monitoring systems and VerifyNow platelet-reactivity testing technology. These solutions support healthcare professionals in making clinical decisions related to transfusion management, bleeding risk assessment and coagulation monitoring. According to Bill Crandell, Vice President of Commercial Operations, North America at Werfen, trauma teams frequently need to make critical treatment decisions within minutes, making access to rapid and actionable coagulation information particularly important. The expanded clearance is intended to help healthcare professionals obtain timely information during trauma resuscitation and support evidence-based treatment strategies. The announcement also reflects the increasing adoption of automated diagnostic technologies in acute care environments, where efficient testing workflows and rapid clinical assessment are essential. Overall, the FDA 510(k) clearance of the ROTEM sigma complete cartridge marks a significant advancement in trauma diagnostics, expanding access to automated coagulation assessment and strengthening Werfen’s position in the global medical diagnostics and healthcare technology market.
Source: Werfen press release



